(IARC) G. Section of Cancer Information. 2018.

Bùi Diệu, Nguyễn Bá Đức, Trần Văn Thuấn Tình hình mắc ung thư tại Việt Nam 2004 - 2008 qua số liệu của 6 vùng. Tạp chí Ung thư học Việt Nam. 2010.

Prof James C-H Yang M, Lecia V Sequist, MD, Sarayut Lucien Geater, MD, Prof Chun-Ming Tsai, MD, Prof Tony Shu Kam Mok, MD, Prof Martin Schuler, MD et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet Oncology. 2015;16:830-838.

Zhou C WY-L, Chen G, et al. OPTIMAL, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open- label, randomised, phase 3 study. The Lancet Oncology. 2011;12:735-742.

Rosell R CE, Gervais R, et al Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239.

Mok TS WY, Thongprasert S, et al Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: 947.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41-50.

James Chih-Hsin Yang M, PhD, Martin Schuler, MD, Sanjay Popat, FRCP, PhD, Keunchil Park, MD, Angela Märten, PhD, Edward S. Kim, MD. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology. January 10, 2020;15:803-815.

Helena Čoupková RV. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report. 2018;31:380-383.

Jang Ho Cho M, 2; Sung Hee Lim, MD3; Ho Jung An, MD, PhD4; Ki Hwan Kim, MD5; Keon Uk Park, MD, PhD6; Eun Joo Kang, MD, PhD7; Yoon Hee Choi, MD8; Mi Sun Ahn, MD9; Myung Hee Lee, PhD10; Jong-Mu Sun, MD, PhD1; Se-Hoon Lee, MD, PhD1;Jin Seok Ahn, MD, PhD1; Keunchil Park, MD, PhD1; and Myung-Ju Ahn, MD, PhD. Osimertinib for Patients With Non–Small-CellLung Cancer Harboring Uncommon EGFRMutations: A Multicenter, Open-Label, Phase IITrial (KCSG-LU15-09). J Clin Oncol. 2019;1:488-495.

Nicolas Floc’h SL, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho and Paul D. Smith. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Molecular Cancer Therapeutics. November 2020;19:2298-307.

Jang Ho Cho M, 2; Sung Hee Lim, MD3; Ho Jung An, MD, PhD4; Ki Hwan Kim, MD5; Keon Uk Park, MD, PhD6; Eun Joo Kang, MD, PhD7;, Yoon Hee Choi MMSA, MD9; Myung Hee Lee, PhD10; Jong-Mu Sun, MD, PhD1; Se-Hoon Lee, MD, PhD1;, Jin Seok Ahn M, PhD1; Keunchil Park, MD, PhD1; and Myung-Ju Ahn, MD, PhD.

. J Clin Oncol. 2019:488-495.

Greulich H, Chen T-H, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor- sensitive and-resistant EGFR mutants. PLoS medicine. 2005;2:e313.

Hirsch FR V-GM, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.

Rosselle T Dungo 1 GMK. Afatinib: first global approval. Pubmed.gov. 2013 Sep;73:1503-15.

.

Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, et al. Molecular dynamics simulation- guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proceedings of the National Academy of Sciences. 2019;116:10025-10030.

Yang JC SL, Geater SL, et al. : Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: Acombined post- hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015:830-838.

Beau-Faller M, Prim N, Ruppert A-M, Nanni-Metéllus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC- IFCT network. Annals of oncology. 2014;25:126-131.

Brückl W, Laack E, Hoffmann C, Zhou C, Wu Y-L. Afatinib in EGFR mutation-positive NSCLC harboring uncommon mutations: experience in ‘real-world’clinical practice.

Yang JC-H, Shih J-Y, Su W-C, Hsia T-C, Tsai C-M, Ou S-HI, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX- Lung 2): a phase 2 trial. 2012;13:539-548.

Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N, et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Science translational medicine. 2017;9:eaan6566.

Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik J-L, et al. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Annals of Oncology. 2022.

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, et al. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). Lung Cancer. 2019;127:103-111.

Wu YL ZC, Hu CP, Feng J, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014 Feb;15:213-222.

Yang J-H, Sequist L, Zhou C, Schuler M, Geater SL, Mok T, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. 2016;27:2103-2110.